Literature DB >> 2725868

Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test.

B Pillon1, B Dubois, A M Bonnet, M Esteguy, J Guimaraes, J M Vigouret, F Lhermitte, Y Agid.   

Abstract

To evaluate clinically the slowing of cognitive processing in Parkinson's disease, we used a visual discrimination task consisting of 15 superimposed images of objects. The time needed to identify 12 objects increased by 58% in 70 patients withdrawn from levodopa treatment compared with 20 controls matched for age and education. Perceptual, motor, and psycholinguistic factors, as well as mood, only partially accounted for the slowness of performance. The 15-objects test scores of the parkinsonian patients correlated significantly with both their intellectual impairment and the severity of their parkinsonian disability, but not with the duration of the disease. The scores did not correlate with depression. Levodopa had no effect on the score, although the parkinsonian motor disability score was improved by 54%. The results indicate a cognitive slowing in Parkinson's disease which is probably related to abnormalities of nondopaminergic neuronal systems in the brain.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2725868     DOI: 10.1212/wnl.39.6.762

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  26 in total

1.  Neuropsychological abnormalities in first degree relatives of patients with familial Parkinson's disease.

Authors:  K Dujardin; A Duhamel; E Becquet; C Grunberg; L Defebvre; A Destee
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Russian neuropsychology after Luria.

Authors:  J M Glozman
Journal:  Neuropsychol Rev       Date:  1999-03       Impact factor: 7.444

3.  Normative data of a brief neuropsychological battery for Spanish individuals older than 49.

Authors:  Montserrat Alegret; Ana Espinosa; Georgina Vinyes-Junqué; Sergi Valero; Isabel Hernández; Lluís Tárraga; James T Becker; Mercè Boada
Journal:  J Clin Exp Neuropsychol       Date:  2011-12-13       Impact factor: 2.475

Review 4.  Deterioration of dopaminergic pathways and alterations in cognition and motor functions.

Authors:  B Dubois; B Pillon; Y Agid
Journal:  J Neurol       Date:  1992       Impact factor: 4.849

5.  Functional neural substrates of posterior cortical atrophy patients.

Authors:  H Shames; N Raz; Netta Levin
Journal:  J Neurol       Date:  2015-05-16       Impact factor: 4.849

6.  Neuropsychological prediction of dementia in Parkinson's disease.

Authors:  F Mahieux; G Fénelon; A Flahault; M J Manifacier; D Michelet; F Boller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

7.  SPECT neuroimaging and neuropsychological functions in different stages of Parkinson's disease.

Authors:  Anna Paschali; Lambros Messinis; Odysseas Kargiotis; Velissarios Lakiotis; Zinovia Kefalopoulou; Costantinos Constantoyannis; Panagiotis Papathanasopoulos; Pavlos Vassilakos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-10       Impact factor: 9.236

Review 8.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

9.  Detection of visuoperceptual deficits in preclinical and mild Alzheimer's disease.

Authors:  Montse Alegret; Mercè Boada-Rovira; Georgina Vinyes-Junqué; Sergi Valero; Ana Espinosa; Isabel Hernández; Gemma Modinos; Maitee Rosende-Roca; Ana Mauleón; James T Becker; Lluís Tárraga
Journal:  J Clin Exp Neuropsychol       Date:  2009-01-14       Impact factor: 2.475

10.  Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Argelia Esperanza Rojas-Mayorquin; Claudia P Figueiredo; Filipe C Matheus; Laure Ginestet; Caroline Chevarin; Elaine Del Bel; Raymond Mongeau; Michel Hamon; Laurence Lanfumey; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2009-07-21       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.